Regeneron vs Figma

Side-by-side comparison of AI visibility scores, market position, and capabilities

Figma leads in AI visibility (99 vs 75)
Regeneron logo

Regeneron

LeaderLife Sciences & BioTech

Biopharmaceuticals

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.

AI VisibilityBeta
Overall Score
B75
Category Rank
#2 of 2
AI Consensus
73%
Trend
up
Per Platform
ChatGPT
72
Perplexity
76
Gemini
84

About

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.

Full profile
Figma logo

Figma

LeaderDesign & Creative Tools

Design & Collaboration

Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.

AI VisibilityBeta
Overall Score
A99
Category Rank
#1 of 1
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
90
Perplexity
99
Gemini
97

About

Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.

Full profile

AI Visibility Head-to-Head

75
Overall Score
99
#2
Category Rank
#1
73
AI Consensus
77
up
Trend
stable
72
ChatGPT
90
76
Perplexity
99
84
Gemini
97
77
Claude
94
79
Grok
99

Key Details

Category
Biopharmaceuticals
Design & Collaboration
Tier
Leader
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Regeneron
Biopharmaceuticals
Only Figma
Design & Collaboration

Integrations

Figma is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.